

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 47/48, 38/44, C12N 9/06</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 00/07629</b> <b>(43) International Publication Date:</b> 17 February 2000 (17.02.00)
<b>(21) International Application Number:</b> PCT/US99/17514 <b>(22) International Filing Date:</b> 2 August 1999 (02.08.99)  <b>(30) Priority Data:</b> 09/130,392                      6 August 1998 (06.08.98)                      US  <b>(71) Applicants (for all designated States except US):</b> MOUNTAIN VIEW PHARMACEUTICALS, INC. [US/US]; 3475-S Edison Way, Menlo Park, CA 94025-1813 (US). DUKE UNIVERSITY [US/US]; University Office of Science and Technology, North Building, Room 230, Science Drive, Box 90083, Durham, NC 27708 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> WILLIAMS, L., David [US/US]; 37709 Arlene Court, Fremont, CA 94536 (US). HERSHFELD, Michael, S. [US/US]; 4019 Bristol Road, Durham, NC 27707 (US). KELLY, Susan, J. [US/US]; 8104 Lair Court, Chapel Hill, NC 27516 (US). SAIFER, Mark, G., P. [US/US]; 1114 Royal Lane, San Carlos, CA 94070 (US). SHERMAN, Merry, R. [US/US]; 1114 Royal Lane, San Carlos, CA 94070 (US).	<b>(74) Agent:</b> ALTMAN, Daniel, E.; Knobbe, Martens, Olson & Bear, LLP, 16th floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).  <b>(81) Designated States:</b> AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>  <b>(88) Date of publication of the international search report:</b> 8 June 2000 (08.06.00)	
<b>(54) Title:</b> PEG-URATE OXIDASE CONJUGATES AND USE THEREOF  <b>(57) Abstract</b>  A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75 % of the uricolytic activity of the unmodified enzyme.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## PEG-URATE OXIDASE CONJUGATES AND USE THEREOF

### Statement of Government Rights

A portion of the research described in this application was made with support from Grant DK48529 from the National Institutes of Health. Accordingly, the U.S. government  
5 may have certain rights in this invention.

### Field of the Invention

The present invention relates to chemical modification of proteins to prolong their circulating lifetimes and reduce their immunogenicity. More specifically, the invention relates to conjugation of poly(ethylene glycols) or poly(ethylene oxides) to urate oxidases,  
10 which substantially eliminates urate oxidase immunogenicity without compromising its uricolytic activity.

### Background of the Invention

Statements contained in this background section do not constitute an admission of prior art, but instead reflect the inventors' own subjective comments on and interpretations  
15 of the state of the art at the time the invention was made. These interpretations may include personal, heretofore undisclosed, insights of the inventors, which insights were not themselves part of the prior art.

Urate oxidases (uricases; E.C. 1.7.3.3) are enzymes that catalyze the oxidation of uric acid to a more soluble product, allantoin, a purine metabolite that is more readily  
20 excreted. Humans do not produce enzymatically active uricase, as a result of several mutations in the gene for uricase acquired during the evolution of higher primates. Wu, X, *et al.*, (1992) *J Mol Evol* 34:78-84. As a consequence, in susceptible individuals, excessive concentrations of uric acid in the blood (hyperuricemia) and in the urine (hyperuricosuria) can lead to painful arthritis (gout), disfiguring urate deposits (tophi) and renal failure. In  
25 some affected individuals, available drugs such as allopurinol (an inhibitor of uric acid synthesis) produce treatment-limiting adverse effects or do not relieve these conditions adequately. Hande, KR, *et al.*, (1984) *Am J Med* 76:47-56; Fam, AG, (1990) *Baillière's Clin Rheumatol* 4:177-192. Injections of uricase can decrease hyperuricemia and hyperuricosuria, at least transiently. Since uricase is a foreign protein in humans, however,  
30 even the first injection of the unmodified protein from *Aspergillus flavus* has induced anaphylactic reactions in several percent of treated patients (Pui, C-H, *et al.*, (1997) *Leukemia* 11:1813-1816), and immunologic responses limit its utility for chronic or

intermittent treatment. Donadio, D, *et al.*, (1981) *Nouv Presse Méd* 10:711-712; Leaustic, M, *et al.*, (1983) *Rev Rhum Mal Osteoartic* 50:553-554.

The sub-optimal performance of available treatments for hyperuricemia has been recognized for several decades. Kissel, P, *et al.*, (1968) *Nature* 217:72-74. Similarly, the possibility that certain groups of patients with severe gout might benefit from a safe and effective form of injectable uricase has been recognized for many years. Davis, FF, *et al.*, (1978) in GB Broun, *et al.*, (Eds.) *Enzyme Engineering, Vol. 4* (pp. 169-173) New York, Plenum Press; Nishimura, H, *et al.*, (1979) *Enzyme* 24:261-264; Nishimura, H, *et al.*, (1981) *Enzyme* 26:49-53; Davis, S, *et al.*, (1981) *Lancet* 2(8241):281-283; Abuchowski, A, *et al.*, (1981) *J Pharmacol Exp Ther* 219:352-354; Chen, RH-L, *et al.*, (1981) *Biochim Biophys Acta* 660:293-298; Chua, CC, *et al.*, (1988) *Ann Int Med* 109:114-117; Greenberg, ML, *et al.*, (1989) *Anal Biochem* 176:290-293. Uricases derived from animal organs are nearly insoluble in solvents that are compatible with safe administration by injection. U.S. Patent 3,616,231. Certain uricases derived from plants or from microorganisms are more soluble in medically acceptable solvents. However, injection of the microbial enzymes quickly induces immunological responses that can lead to life-threatening allergic reactions or to inactivation and/or accelerated clearance of the uricase from the circulation. Donadio, *et al.*, (1981); Leaustic, *et al.*, (1983). Enzymes based on the deduced amino acid sequences of uricases from mammals, including pig and baboon, or from insects, such as, for example, *Drosophila melanogaster* or *Drosophila pseudoobscura* (Wallrath, LL, *et al.*, (1990) *Mol Cell Biol* 10:5114-5127), have not been suitable candidates for clinical use, due to problems of immunogenicity and insolubility at physiological pH.

Covalent modification of proteins with poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), has been used to increase protein half-life and reduce immunogenicity. U.S. Patents 4,179,337, 4,766,106, and 4,847,325; Saifer, MGP, *et al.*, (1994) *Adv Exp Med Biol* 366:377-387. The coupling of PEG of high molecular weight to produce conjugates with prolonged circulating lifetimes and/or decreased immunogenicity, while conserving functional activity, was previously demonstrated for another enzyme, superoxide dismutase (Somack, R, *et al.*, (1991) *Free Rad Res Commun* 12-13:553-562; U.S. Patents 5,283,317 and 5,468,478) and for other types of proteins, e.g., cytokines (Saifer, MGP, *et al.*, (1997) *Polym Preprints* 38:576-577; Sherman, MR, *et al.*, (1997) in JM Harris, *et al.*, (Eds.), *Poly(ethylene glycol) Chemistry and Biological Applications*. ACS

*Symposium Series 680* (pp. 155-169) Washington, DC: American Chemical Society).  
Conjugates of uricase with polymers other than PEG have also been described. U.S. Patent 4,460,683.

In nearly all of the reported attempts to PEGylate uricase (*i.e.* to covalently couple  
5 PEG to uricase), the PEG was attached primarily to amino groups, including the amino-terminal residue and the available lysine residues. In the uricases commonly used, the total number of lysines in each of the four identical subunits is between 25 (*Aspergillus flavus* (U.S. Patent 5,382,518)) and 29 (pig (Wu, X, *et al.*, (1989) *Proc Natl Acad Sci USA* 86:9412-9416)). Some of the lysines are unavailable for PEGylation in the native  
10 conformation of the enzyme. The most common approach to reducing the immunogenicity of uricase has been to couple large numbers of strands of low molecular weight PEG. This has invariably resulted in large decreases in the enzymatic activity of the resultant conjugates.

Previous investigators have used injected uricase to catalyze the conversion of uric  
15 acid to allantoin *in vivo*. See Pui, *et al.*, (1997). This is the basis for the use in France and Italy of uricase from the fungus *Aspergillus flavus* (Uricozyme®) to prevent or temporarily correct the hyperuricemia associated with cytotoxic therapy for hematologic malignancies and to transiently reduce severe hyperuricemia in patients with gout. Potaux, L, *et al.*, (1975) *Nouv Presse Méd* 4:1109-1112; Legoux, R, *et al.*, (1992) *J Biol Chem* 267:8565-  
20 8570; U.S. Patents 5,382,518 and 5,541,098. Because of its short circulating lifetime, Uricozyme® requires daily injections. Furthermore, it is not well suited for long-term therapy because of its immunogenicity.

A single intravenous injection of a preparation of *Candida utilis* uricase coupled to  
5 kDa PEG reduced serum urate to undetectable levels in five human subjects whose  
25 average pre-injection serum urate concentration was 6.2 mg/dL, which is within the normal range. Davis, *et al.*, (1981). The subjects were given an additional injection four weeks later, but their responses were not reported. No antibodies to uricase were detected following the second (and last) injection, using a relatively insensitive gel diffusion assay. This reference reported no results from chronic or subchronic treatments of human patients  
30 or experimental animals.

A preparation of uricase from *Arthrobacter protoformiae* coupled to 5 kDa PEG was used to temporarily control hyperuricemia in a single patient with lymphoma whose

pre-injection serum urate concentration was 15 mg/dL. Chua, *et al.*, (1988). Because of the critical condition of the patient and the short duration of treatment (four injections during 14 days), it was not possible to evaluate the long-term efficacy or safety of the conjugate.

5        In this application, the term "immunogenicity" refers to the induction of an immune response by an injected preparation of PEG-modified or unmodified uricase (the antigen), while "antigenicity" refers to the reaction of an antigen with preexisting antibodies. Collectively, antigenicity and immunogenicity are referred to as "immunoreactivity." In previous studies of PEG-uricase, immunoreactivity was assessed by a variety of methods,  
10        including: 1) the reaction *in vitro* of PEG-uricase with preformed antibodies; 2) measurements of induced antibody synthesis; and 3) accelerated clearance rates after repeated injections.

Previous attempts to eliminate the immunogenicity of uricases from several sources by coupling various numbers of strands of PEG through various linkers have met with  
15        limited success. PEG-uricases were first disclosed by FF Davis and by Y Inada and their colleagues. Davis, *et al.*, (1978); U.S. Patent 4,179,337; Nishimura, *et al.*, (1979); Japanese Patents 55-99189 and 62-55079. The conjugate disclosed in the '337 patent was synthesized by reacting uricase of unspecified origin with a 2,000-fold molar excess of 750 dalton PEG, indicating that a large number of polymer molecules was likely to have been  
20        attached to each uricase subunit. The '337 patent discloses the coupling of either PEG or poly(propylene glycol) with molecular weights of 500 to 20,000 daltons, preferably about 500 to 5,000 daltons, to provide active, water-soluble, non-immunogenic conjugates of various polypeptide hormones and enzymes including oxidoreductases, of which uricase is one of three examples. In addition, the '337 patent emphasizes the coupling of 10 to 100  
25        polymer strands per molecule of enzyme, and the retention of at least 40% of enzymatic activity. No test results were reported for the extent of coupling of PEG to the available amino groups of uricase, the residual specific uricolytic activity, or the immunoreactivity of the conjugate.

Data from 13 citations relating to PEGylation of uricase are summarized in Table 1.  
30        Some of these results are also presented graphically in Figures 1A-2B. Seven of these publications describe significant decreases in uricolytic activity measured *in vitro* caused by coupling various numbers of strands of PEG to uricase from *Candida utilis*. Coupling a

large number of strands of 5 kDa PEG to porcine liver uricase gave similar results, as described in both the Chen publication and a symposium report by the same group. Chen, *et al.*, (1981); Davis, *et al.*, (1978).

Among the studies summarized in Table 1, the immunoreactivity of uricase was reported to be decreased by PEGylation in seven of them and eliminated in five of them. In three of the latter five studies, the elimination of immunoreactivity was associated with profound decreases in uricolytic activity – to at most 15%, 28%, or 45% of the initial activity. Nishimura, *et al.*, (1979) (15% activity); Chen, *et al.*, (1981) (28% activity); Nishimura, *et al.*, (1981) (45% activity). In the fourth report, PEG was reported to be coupled to 61% of the available lysine residues, but the residual specific activity was not stated. Abuchowski, *et al.*, (1981). However, a research team that included two of the same scientists and used the same methods reported elsewhere that this extent of coupling left residual activity of only 23-28%. Chen, *et al.*, (1981). The 1981 publications of Abuchowski *et al.*, and Chen *et al.*, indicate that to reduce the immunogenicity of uricase substantially, PEG must be coupled to approximately 60% of the available lysine residues (Table 1). The fifth publication in which the immunoreactivity of uricase was reported to have been eliminated does not disclose the extent of PEG coupling, the residual uricolytic activity, or the nature of the PEG-protein linkage. Veronese, FM, *et al.*, (1997) in JM Harris, *et al.*, (Eds.), *Poly(ethylene glycol) Chemistry and Biological Applications. ACS Symposium Series 680* (pp. 182-192) Washington, DC: American Chemical Society.

Conjugation of PEG to a smaller fraction of the lysine residues in uricase reduced but did not eliminate its immunoreactivity in experimental animals. Tsuji, J, *et al.*, (1985) *Int J Immunopharmacol* 7:725-730 (28-45% of the amino groups coupled); Yasuda, Y, *et al.*, (1990) *Chem Pharm Bull* 38:2053-2056 (38% of the amino groups coupled). The residual uricolytic activities of the corresponding adducts ranged from <33% (Tsuji, *et al.*) to 60% (Yasuda, *et al.*) of their initial values. Tsuji, *et al.*, synthesized PEG-uricase conjugates with 7.5 kDa and 10 kDa PEGs, in addition to 5 kDa PEG. All of the resultant conjugates were somewhat immunogenic and antigenic, while displaying markedly reduced enzymatic activities (Table 1; Figures 1A-1B).

A PEGylated preparation of uricase from *Candida utilis* that was safely administered twice to each of five humans was reported to have retained only 11% of its initial activity. Davis, *et al.*, (1981). Several years later, PEG-modified uricase from

*Arthrobacter protoformiae* was administered four times to one patient with advanced lymphoma and severe hyperuricemia. Chua, *et al.*, (1988). While the residual activity of that enzyme preparation was not measured, Chua, *et al.*, demonstrated the absence of anti-uricase antibodies in the patient's serum 26 days after the first PEG-uricase injection, using an enzyme-linked immunosorbent assay (ELISA).

As summarized in Table 1, previous studies of PEGylated uricase show that catalytic activity is markedly depressed by coupling a sufficient number of strands of PEG to decrease its immunoreactivity substantially. Furthermore, most previous preparations of PEG-uricase were synthesized using PEG activated with cyanuric chloride, a triazine derivative (2,4,6-trichloro-1,3,5-triazine) that has been shown to introduce new antigenic determinants and to induce the formation of antibodies in rabbits. Tsuji, *et al.*, (1985).

**TABLE 1: Characteristics of PEG-uricases from Previous Studies**

Source of Uricase	Coupling Linkage	Molecular Weight of PEG (kDa)	Percent of Lysines with PEG Attached	Residual Uricolytic Activity (%)	Antigenicity or Immunogenicity Comments	Reference
Not reported	Azide	0.7 (diol)	Not reported	Not reported	Not reported	U.S. Patent 4,179,337
<i>Candida utilis</i>	Triazine (Cyanuric chloride)	5	% of "98": 20 26 43 48	31 21 15 5	Antigenicity with rabbit serum (% of that of the unmodified enzyme) 70% 6% 0 0	Nishimura, <i>et al.</i> , 1979
<i>Candida utilis</i>	PEG <sub>2</sub> triazine	2 x 5	22 25 36 46 50	87 70 45 31 27	86% 49% 0 0 0	Nishimura, <i>et al.</i> , 1981



Source of Uricase	Coupling Linkage	Molecular Weight of PEG (kDa)	Percent of Lysines with PEG Attached	Residual Uricolytic Activity (%)	Antigenicity or Immunogenicity <i>Comments</i>	Reference
<i>Candida utilis</i>	Triazine	5	71	11	Five men tolerated two injections in 30 days.	Davis, <i>et al.</i> , 1981
<i>Candida utilis</i>	Triazine according to Chen, <i>et al.</i> , 1981	5	49 61	Not reported Not reported	Similar immunogenicity in birds to native uricase  Immunogenicity negative	Abuchowski, <i>et al.</i> , 1981
Porcine liver	Triazine	5	37 47 58	60 45 28	Accelerated clearance in mice " " " " " " Constant Clearance (half-life <i>ca.</i> 8 hours)	Chen, <i>et al.</i> , 1981
<i>Candida utilis</i>	Triazine	5	57	23	Constant Clearance (half-life <i>ca.</i> 8 hours)	
<i>Candida utilis</i>	Triazine according to Chen, <i>et al.</i> , 1981	5	35 70	Not reported Not reported	PEG decreased immunogenicity in rabbits. " " " "	Savoca, KV, <i>et al.</i> , (1984) <i>Int Arch Allergy Appl Immunol</i> 75:58-67
<i>Candida utilis</i>	Triazine	5	Not reported	Not reported	PEG-uricase was given orally to chickens in liposomes (once).	Nishida, Y, <i>et al.</i> , (1984) <i>J Pharm Pharmacol</i> 36:354-355

Source of Uricase	Coupling Linkage	Molecular Weight of PEG (kDa)	Percent of Lysines with PEG Attached	Residual Uricolytic Activity (%)	Antigenicity or Immunogenicity <i>Comments</i>	Reference
<i>Candida utilis</i>	Triazine	5	44	9.4	Immunogenicity reduced, but positive in rabbits. (Antibodies are not to uricase; they cross react with PEG-superoxide dismutase.) Antigenicity tested with guinea pig antibodies was reduced.	Tsuji, <i>et al.</i> , 1985
		7.5	45	7.8		
		10	28	32		
			37	11		
			41	3		
			45	7.3		
<i>Arthrobacter protoformiae</i>	Not reported	5	Not reported	Not reported	No antibodies were detected by ELISA 26 days after the first of four PEG-uricase injections.	Chua, <i>et al.</i> , 1988
<i>Candida utilis</i>	PEG <sub>2</sub> triazine	2 x 5	10	90	Not reported	Yasuda, <i>et al.</i> , 1990
			12	89	Not reported	
			15	80	Not reported	
			21	70	Not reported	
			38	60	Antigenicity tested with rabbit serum was reduced by 75%.	
<i>Candida utilis</i>	PEG <sub>2</sub> triazine	2 x 5	22	68	Single injection. PEG increased the half-life from ca. 1 h to ca. 8 h in mice. PEG blocked clearance by liver, spleen and kidney (24-h study duration).	Fujita, <i>et al.</i> , 1991

Source of Uricase	Coupling Linkage	Molecular Weight of PEG (kDa)	Percent of Lysines with PEG Attached	Residual Uricolytic Activity (%)	Antigenicity or Immunogenicity Comments	Reference
Not reported	PEG	Not reported	Not reported	Not reported	Immunogenicity in mice was decreased by 98% (PEG) or 100% (PEG <sub>2</sub> ).	Veronese, <i>et al.</i> , 1997
	PEG <sub>2</sub>		Reported to be the same as for PEG	Not reported		
	Linkage not stated					

Japanese Patent 3-148298 to A Sano, *et al.*, discloses modified proteins, including uricase, derivatized with PEG having a molecular weight of 1-12 kDa that show reduced antigenicity and "improved prolonged" action, and methods of making such derivatized peptides. However, there are no disclosures regarding strand counts, enzyme assays, biological tests or the meaning of "improved prolonged." Japanese Patents 55-99189 and 62-55079, both to Y Inada, disclose uricase conjugates prepared with PEG-triazine or bis-PEG-triazine (denoted as PEG<sub>2</sub> in Table 1), respectively. See Nishimura, *et al.*, (1979 and 1981). In the first type of conjugate, the molecular weights of the PEGs were 2 kDa and 5 kDa, while in the second, only 5 kDa PEG was used. Nishimura, *et al.*, (1979) reported the recovery of 15% of the uricolytic activity after modification of 43% of the available lysines with linear 5 kDa PEG, while Nishimura, *et al.*, (1981) reported the recovery of 31% or 45% of the uricolytic activity after modification of 46% or 36% of the lysines, respectively, with PEG<sub>2</sub>.

#### Summary of the Invention

Previous studies teach that when a significant reduction in the immunogenicity and/or antigenicity of uricase is achieved by PEGylation, it is invariably associated with a substantial loss of uricolytic activity. The safety, convenience and cost-effectiveness of biopharmaceuticals are all adversely impacted by decreases in their potencies and the resultant need to increase the administered dose. Thus, there is a need for a safe and effective alternative means for lowering elevated levels of uric acid in body fluids,

including blood and urine. The present invention provides a substantially non-immunogenic PEG-uricase that retains all or nearly all of the uricolytic activity of the unmodified enzyme.

One embodiment of the present invention is a conjugate of urate oxidase (uricase) 5 that retains at least about 75% of the uricolytic activity of unconjugated uricase and has substantially reduced immunogenicity. This embodiment includes a purified uricase in which each subunit may be covalently linked to an average of 2 to 10 strands of PEG, which may be linear or branched, wherein each molecule of PEG may have a molecular weight between about 5 kDa and 100 kDa. The uricase of this aspect of the invention may 10 be recombinant. Whether recombinant or not, the uricase may be of mammalian origin. In one aspect of this embodiment, the uricase may be porcine, bovine or ovine liver uricase. In another aspect of this embodiment, the uricase may be chimeric. The chimeric uricase may contain portions of porcine liver and/or baboon liver uricase. For example, the chimeric uricase may be pig-baboon chimeric uricase (PBC uricase) or porcine uricase 15 containing the mutations R291K and T301S (PKS uricase) (see sequences in Figure 6 and results of physiological and immunological studies in Figures 7-12). Alternatively, the uricase may be baboon liver uricase in which tyrosine 97 has been replaced by histidine, whereby the specific activity of the uricase may be increased by at least about 60%. The uricase of the invention, whatever the origin, may also be in a form that is truncated, either 20 at the amino terminal, or at the carboxyl terminal, or at both terminals. Likewise, the uricase may be fungal or microbial uricase. In one aspect of this embodiment, the fungal or microbial uricase may be a naturally occurring or recombinant form of uricase from *Aspergillus flavus*, *Arthrobacter globiformis* or *Candida utilis*. Alternatively, the uricase may be an invertebrate uricase, such as, for example, a naturally occurring or recombinant 25 form of uricase from *Drosophila melanogaster* or *Drosophila pseudoobscura*. The uricase of the invention may also be a plant uricase, for example, a naturally occurring or recombinant form of uricase from soybean root nodule (*Glycine max*). The PEG may have an average molecular weight between about 5 kDa and 100 kDa; preferably the PEG may have an average molecular weight between about 10 kDa and 60 kDa; more preferably, the 30 PEG may have an average molecular weight between about 20 kDa and about 40 kDa, such as, for example, 30 kDa. The average number of covalently coupled strands of PEG may be 2 to 10 strands per uricase subunit; preferably, the average number of covalently coupled

strands may be 3 to 8 per subunit; more preferably, the average number of strands of PEG may be 4 to 6 per subunit. In one aspect of this embodiment, the uricase may be tetrameric. The strands of PEG may be covalently linked to uricase via urethane (carbamate) linkages, secondary amine linkages, and/or amide linkages. When the uricase is a recombinant form  
5 of any of the uricases mentioned herein, the recombinant form may have substantially the sequence of the naturally occurring form.

Another embodiment of the present invention is a pharmaceutical composition for lowering uric acid levels in body fluids, containing any of the PEG-uricase conjugates described above and a pharmaceutically acceptable carrier. The composition may be  
10 stabilized by lyophilization and also may dissolve promptly upon reconstitution to provide solutions suitable for parenteral administration.

The present invention also provides a method for lowering uric acid levels in body fluids and tissues of a mammal. The method includes administering to a mammal an effective uric acid-lowering amount of PEG-uricase. The PEG-uricase may be a purified  
15 uricase of two or more subunits in which each subunit may be covalently linked to an average of 2 to 10 strands of linear or branched PEG, wherein each molecule of PEG may have a molecular weight between about 5 kDa and 100 kDa, in a pharmaceutically acceptable carrier. The mammal may be a human. The administering step may be, for example, injection by intravenous, intradermal, subcutaneous, intramuscular or  
20 intraperitoneal routes or inhalation of an aerosolized preparation. The elevated uric acid levels may be in blood, urine and/or other body fluids and tissues, and may be associated with gout, tophi, renal insufficiency, organ transplantation or malignant disease.

Other embodiments of the present invention are a method for isolating a tetrameric form of uricase from a solution containing multiple forms of uricase and the product of that  
25 method. Initially, the solution may contain tetrameric uricase and uricase aggregates. The method may include the steps of: applying the solution to at least one separation column at a pH between about 9 and 10.5, such as, for example, 10.2; recovering fractions of the eluate and identifying those that may contain isolated tetrameric uricase, wherein the fractions are substantially free of uricase aggregates; and pooling the fractions of the  
30 isolated tetrameric uricase. The separation column may be based on ion exchange, size exclusion, or any other effective separation property. The method may also include analysis of the fractions to determine the presence of tetrameric uricase and/or the absence

of uricase aggregates. For example, such analysis may include high performance liquid chromatography (HPLC), other chromatographic methods, light scattering, centrifugation and/or electrophoresis. In one aspect of this embodiment, the purified tetrameric uricase may contain less than about 10% uricase aggregates.

5

#### Brief Description of the Drawings

Figure 1A shows the retention of activity by PEGylated uricase from *Candida utilis* as a function of the number of strands of PEG coupled per subunit.

Figure 1B shows the retention of activity by PEGylated uricase from *Candida utilis* as a function of the total mass of PEG coupled per subunit.

10

Figure 2A shows the retention of activity by PEGylated uricase from porcine liver as a function of the number of strands of PEG coupled per subunit.

Figure 2B shows the retention of activity by PEGylated uricase from porcine liver as a function of the total mass of PEG coupled per subunit.

Figure 3A shows the retention of activity by PEGylated pig-baboon chimeric (PBC) uricase as a function of the number of strands coupled per subunit.

15

Figure 3B shows the retention of activity by PEGylated PBC uricase as a function of the total mass of PEG coupled per subunit.

Figure 4A shows the retention of activity by PEGylated uricase from *Aspergillus flavus* as a function of the number of strands of PEG coupled per subunit.

20

Figure 4B shows the retention of activity by PEGylated uricase from *Aspergillus flavus* as a function of the total mass of PEG coupled per subunit.

Figure 5A shows the retention of activity by PEGylated recombinant soybean root nodule uricase as a function of the number of strands of PEG coupled per subunit.

Figure 5B shows the retention of activity by PEGylated recombinant soybean root nodule uricase as a function of the total mass of PEG coupled per subunit.

25

Figure 6 shows the deduced amino acid sequences of pig-baboon chimeric uricase (PBC uricase), PBC uricase that is truncated at both the amino and carboxyl terminals (PBC-NT-CT) and porcine uricase containing the mutations R291K and T301S (PKS uricase), compared with the porcine and baboon sequences.

30

Figure 7 shows the activity of uricase in mouse serum 24 h after each of four or five intraperitoneal injections of PEG-modified PBC uricase, relative to the value 24 h after the first injection.

Figure 8 shows the inverse relationship between the activity of injected PEG-modified PBC uricase in the serum of a uricase-deficient mouse and the concentrations of uric acid in the serum and urine.

Figure 9 shows the decreased severity of a urine-concentrating defect in uricase-deficient (*uox* <sup>-/-</sup>) mice that were treated with PEG-modified PBC uricase.

Figure 10 shows the decreased severity of nephrogenic diabetes insipidus in uricase-deficient (*uox* <sup>-/-</sup>) mice that were treated with PEG-modified PBC uricase.

Figure 11 shows the decreased severity of uric acid-induced nephropathy, as visualized by magnetic resonance microscopy, in uricase-deficient (*uox* <sup>-/-</sup>) mice that were treated with PEG-modified PBC uricase.

Figure 12 shows the accelerated clearance from the circulation of BALB/c mice of injected PBC uricase octamer, compared with the tetramer, when both were coupled to 5-6 strands of 10 kDa PEG per subunit.

#### Detailed Description of the Preferred Embodiments

The present invention provides improved conjugates of water-soluble polymers, preferably poly(ethylene glycols) or poly(ethylene oxides), with uricases. The invention also provides pharmaceutical compositions of the improved conjugates. These conjugates are substantially non-immunogenic and retain at least 75%, preferably 85%, and more preferably 95% or more of the uricolytic activity of the unmodified enzyme. Uricases suitable for conjugation to water-soluble polymers include naturally occurring urate oxidases isolated from bacteria, fungi and the tissues of plants and animals, both vertebrates and invertebrates, as well as recombinant forms of uricase, including mutated, hybrid, and/or truncated enzymatically active variants of uricase. Water-soluble polymers suitable for use in the present invention include linear and branched poly(ethylene glycols) or poly(ethylene oxides), all commonly known as PEGs. Examples of branched PEG are the subject of U.S. Patent 5,643,575. One preferred example of linear PEG is monomethoxyPEG, of the general structure  $\text{CH}_3\text{O}-(\text{CH}_2\text{CH}_2\text{O})_n\text{H}$ , where *n* varies from about 100 to about 2,300.

One preferred mammalian uricase is recombinant pig-baboon chimeric uricase, composed of portions of the sequences of pig liver and baboon liver uricase, both of which were first determined by Wu, *et al.*, (1989). One example of such a chimeric uricase contains the first 225 amino acids from the porcine uricase sequence (SEQ ID NO: 1) and

the last 79 amino acids from the baboon uricase sequence (SEQ ID NO: 2) (pig-baboon uricase, or PBC uricase; see Figure 6). Another example of such a chimeric uricase contains residues 7-225 of the porcine sequence (SEQ ID NO. 1) and residues 226-301 of the baboon sequence (SEQ ID NO. 2); this is equivalent to PBC uricase that is truncated at both the amino and carboxyl terminals (PBC-NT-CT; see Figure 6). Another example of such a chimeric uricase contains the first 288 amino acids from the porcine sequence (SEQ ID NO: 1) and the last 16 amino acids from the baboon sequence (SEQ ID NO: 2). Since the latter sequence differs from the porcine sequence at only two positions, having a lysine (K) in place of arginine at residue 291 and a serine (S) in place of threonine at residue 301, this mutant is referred to as pig-K-S or PKS uricase. PKS, PBC and PBC-NT-CT uricases each have one more lysine residue and, hence, one more potential site of PEGylation than either the porcine or baboon sequence.

The cDNAs for various mammalian uricases, including PBC uricase, PKS uricase and a recombinant baboon-like uricase, were subcloned and the optimal conditions were determined for expression in *E. coli*, using standard methods. See Erlich, HA, (Ed.) (1989) *PCR Technology. Principles and Applications for DNA Amplification*. New York: Stockton Press; Sambrook, J, et al., (1989) *Molecular Cloning. A Laboratory Manual, Second Edition*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. The recombinant uricases were extracted, purified and their stability and activity were assessed using a modification of standard assays. See Fridovich, I, (1965) *J Biol Chem* 240:2491-2494; Nishimura, et al., (1979), and Example 1.

In one embodiment of the invention, uricase may be conjugated via a biologically stable, nontoxic, covalent linkage to a relatively small number of strands of PEG. Such linkages may include urethane (carbamate) linkages, secondary amine linkages, and amide linkages. Various activated PEGs suitable for such conjugation are available commercially from Shearwater Polymers, Huntsville, AL.

For example, urethane linkages to uricase may be formed by incubating uricase in the presence of the succinimidyl carbonate (SC) or 4-nitrophenyl carbonate (NPC) derivative of PEG. SC-PEG may be synthesized using the procedure described in U.S. Patent 5,612,460, which is hereby incorporated by reference. NPC-PEG may be synthesized by reacting PEG with 4-nitrophenyl chloroformate according to methods described in Veronese, FM, et al., (1985) *Appl Biochem Biotechnol* 11:141-152, and in



U.S. Patent 5,286,637, which is hereby incorporated by reference. The methods described in the '637 patent are adapted to PEGs of higher molecular weight by adjusting the concentrations of the reactants to maintain similar stoichiometry. An alternative method of synthesis of NPC-PEG is described by Büttner, W, *et al.*, East German Patent Specification  
5 DD 279 486 A1.

Amide linkages to uricase may be obtained using an *N*-hydroxysuccinimide ester of a carboxylic acid derivative of PEG (Shearwater Polymers). Secondary amine linkages may be formed using 2,2,2-trifluoroethanesulfonyl PEG (tresyl PEG; Shearwater Polymers) or by reductive alkylation using PEG aldehyde (Shearwater Polymers) and  
10 sodium cyanoborohydride.

In conjugates containing PEGs with molecular weights between 5 kDa and 30 kDa, the maximum number of strands of PEG that were coupled per subunit, while retaining at least 75% of the uricolytic activity of the unmodified enzyme, ranged from an average of 2 strands for soybean uricase to more than 10 strands for PBC uricase (*see* assay conditions  
15 in Example 1 and results in Figures 1A-5B). The latter extent of PEGylation corresponds to approximately one third of the total amino groups. In one embodiment of the invention, the average number of strands of PEG coupled per uricase subunit is between 2 and 10. In a preferred embodiment, the average number of strands of PEG coupled per uricase subunit is between 3 and 8. In a more preferred embodiment, the average number of covalently  
20 linked strands of PEG per uricase subunit is between 4 and 6. In another embodiment, the molecular weight of PEG used for the coupling reaction is between 5 kDa and 100 kDa, preferably between 10 kDa and 60 kDa, and more preferably between 20 kDa and 40 kDa, such as, for example 30 kDa.

There are several factors that may affect the choice of the optimal molecular weight  
25 and number of strands of PEG for coupling to a given form of uricase. In general, the reduction or elimination of immunogenicity without substantial loss of uricolytic activity may require the coupling of relatively more strands of PEG of lower molecular weight, compared to relatively fewer strands of PEG of higher molecular weight. For example, either 6 strands of 20 kDa PEG per subunit or 4 strands of 30 kDa PEG per subunit might  
30 be optimally effective. Likewise, each different form of uricase may have a different optimum with respect to both the size and number of strands. *See* Figures 1A-5B.

PEG conjugation rendered all of the tested uricases soluble and stable in buffers at physiological pH, without the addition of a substrate analog or inhibitor, such as 8-azaxanthine that is used as a stabilizer in the fungal uricase (Uricozyme®) sold by Sanofi Winthrop in France and Italy. Two different conjugates of PBC uricase, one containing approximately 6 strands of 10 kDa PEG per subunit and the other containing approximately 2 strands of 19 kDa PEG per subunit, retained significant activity after incubation in mouse serum for more than one month at 37°C. In addition, several of the conjugates of this invention had circulating half-lives in mice that were greater than two days, in contrast to the approximately 8-hour or 24-hour half-lives previously reported for PEG-modified mammalian and microbial uricases. Chen, *et al.*, (1981); Fuertges, F, *et al.*, (1990) *J Contr Release* 11: 139-148; Fujita, T, *et al.*, (1991) *J Pharmacobiodyn* 14:623-629. Longer half-lives of injected protein drugs make them more cost-effective and can lead to improved patient compliance. Prolonged half-life is also indicative of products that are better tolerated by the body.

When PEG conjugates of PBC uricase were prepared from the purified tetrameric form of the enzyme (four 35 kDa subunits), they displayed profoundly reduced immunogenicity in mice (Figure 7), in contrast to the moderate immunogenicity of PEG conjugates of larger forms of the enzyme (e.g. octamers of the 35 kDa subunit; see Figure 12), and the very high immunogenicity of the unmodified enzyme. Repeated injections of uricase-deficient mice with PEG-uricase of the present invention eliminated their hyperuricemia for more than 2 months and protected the structure and function of their kidneys against uric acid-related damage (Figures 8-11).

Injections of fully active conjugates of PBC uricase with 10 kDa PEG (Figures 3A-3B) reduced dramatically the hyperuricemia of homozygous, uricase-deficient mice (Figure 8). Uric acid levels in the urine were also reduced dramatically in all uricase-deficient mice treated with PEG-modified PBC uricase. Uricase-deficient mice received a series of injections with a preparation of PEG-uricase similar to that used to obtain the data in Figure 8. This treatment reduced the severity of a urine-concentrating defect, as demonstrated by measurements of urine osmolality under normal conditions and after a 12-hour period of water deprivation (Figure 9) and by their water consumption and urine output (Figure 10), compared to the corresponding measurements in untreated, genetically similar mice. It was also demonstrated that ten weeks of treatment, starting within the first

ten days of life, of homozygous uricase-deficient (*uox* *-/-*) "knockout" mice with a PEG-uricase of this invention decreased the severity of urate-induced disruption of the renal architecture, as visualized by magnetic resonance microscopy (Figure 11). For microscopy methods, see Hedlund, LW, *et al.*, (1991) *Fund Appl Toxicol* 16:787-797; Johnson, GA, *et al.*, (1992) in JC Gore, (Ed.), *Reviews of Magnetic Resonance in Medicine*, Vol. 4 (pp. 187-219) New York: Pergamon Press.

Purified preparations of naturally occurring and recombinant uricases usually contain a mixture of aggregates of the enzyme, in addition to the tetrameric (140 kDa) form. The percentage of each uricase preparation that is in the tetrameric form generally varies from approximately 20% to 90%. Despite evidence that unPEGylated aggregates of several other proteins are highly immunogenic (see, e.g., Moore, WV, *et al.*, (1980) *J Clin Endocrinol Metab* 51:691-697), previous studies of PEG-uricase do not describe any efforts to limit the content of aggregates, suggesting that the potential immunogenicity of the PEG-modified aggregates was not considered. On the basis of the observations of the present inventors, it appears likely that such aggregates were present in the enzyme preparations used for previous syntheses of PEG-uricase. Their presence may have rendered the task of preparing non-immunogenic conjugates more difficult. It also appears that the large losses of uricolytic activity observed in previous efforts to PEGylate uricase were related to the large number of strands of low molecular weight PEG that were coupled. On the other hand, the methods of uricase purification and PEGylation described herein permit the covalent attachment of as many as 10 strands of PEG per subunit while retaining more than 75% of the uricolytic activity, at least for certain uricases, e.g., pig-baboon chimeric uricase and the enzyme from *A. flavus* (see Figures 3A and 4A).

In another preferred embodiment, substantially all aggregates of the tetrameric form of the enzyme may be removed by ion-exchange or size-exclusion chromatography at a pH between about 9 and 10.5, preferably 10.2, prior to PEG conjugation of the resulting substantially tetrameric preparation of uricase. The molecular weight of the uricase in each fraction from the preparative column may be monitored by any size-dependent analytical technique, including, for example, HPLC, conventional size-exclusion chromatography, centrifugation, light scattering, capillary electrophoresis or gel electrophoresis in a non-denaturing buffer. For tetrameric uricase isolated using size-exclusion chromatography, fractions containing only the 140 kDa form of the enzyme may be pooled and used for

conjugation to PEG. For tetrameric uricase isolated using ion-exchange chromatography, fractions from the ion-exchange column may be analyzed with respect to size to determine which fractions contain substantial amounts of the tetrameric form without detectable aggregates. Of the uricase thus pooled, at least 90% may be in the tetrameric form; the undesirable aggregates may thus constitute as little as about 10%, 5%, 2%, or less, of the total isolated uricase.

The results presented herein indicate that, even when extensively PEGylated, forms of PBC uricase larger than the tetramer are highly immunogenic in mice (Figure 12). Furthermore, in mice that had been injected once with PEG conjugates of uricase aggregates, the uricolytic activity in subsequent injections of either PEGylated tetramers or PEGylated aggregates was cleared rapidly from the circulation. In contrast, conjugates prepared from uricase containing less than 5% aggregates could be reinjected many times without any acceleration of their clearance rates (Figure 7) and without the detectable formation of antibodies, as measured by a sensitive enzyme-linked immunoassay. The use of highly purified tetrameric uricase further distinguishes the improved conjugates of the present invention from the PEG-uricase preparations described previously. In contrast, the presence of a significant proportion (e.g., >10%) of aggregates in the uricase preparations used by some previous investigators may have led them to couple large numbers of strands of PEG in efforts to suppress the immunogenicity. Consequently, the enzymatic activity of the resultant conjugates was decreased substantially. In other embodiments, the present invention expressly contemplates PEGylated uricase in non-tetrameric form, such as, for example, uricase dimers, so long as the preparations of such conjugated uricase retain at least about 75% of their uricolytic activity and are substantially non-immunogenic.

In another embodiment of the present invention, a mutated baboon liver uricase of unexpectedly increased potency, relative to that of the unmutated enzyme, is provided. This improved primate uricase was prepared by conventional recombinant DNA techniques. It was particularly unexpected that the substitution of a single amino acid residue (histidine for tyrosine at position 97) in baboon uricase would result in a substantial increase in specific enzymatic activity. When expressed in *E. coli*, this mutant protein was found to have at least 60% higher specific activity than the recombinant baboon enzyme from which it was derived.

In another embodiment, the specific activity is increased and/or the solubility of the unPEGylated enzyme is improved by expressing truncated variants of porcine or porcine-baboon chimeric uricases from which at least the first six amino acids at the amino terminal and/or at least the last three amino acids at the carboxyl terminal are deleted from the expressed proteins (*see* Figure 6). Recombinant uricases with the carboxyl-terminal truncation may have improved solubility prior to PEGylation because of the removal of the peroxisomal targeting sequence. *See* Miura, S, *et al.*, (1994) *Eur J Biochem* 223:141-146.

The PEG-uricase conjugates of the present invention are useful for lowering the levels of uric acid in the body fluids and tissues of mammals, preferably humans, and can thus be used for treatment of elevated uric acid levels associated with conditions including gout, tophi, renal insufficiency, organ transplantation and malignant disease. PEG-uricase conjugates may be injected into a mammal having excessive uric acid levels by any of a number of routes, including intravenous, subcutaneous, intradermal, intramuscular and intraperitoneal routes. Alternatively, they may be aerosolized and inhaled. *See* Patton, JS, (1996) *Adv Drug Delivery Rev* 19:3-36 and U.S. Patent 5,458,135. The effective dose of PEG-uricase of the present invention will depend on the level of uric acid and the size of the individual. In one embodiment of this aspect of the invention, PEG-uricase is administered in a pharmaceutically acceptable excipient or diluent in an amount ranging from about 10 µg to about 1 g. In a preferred embodiment, the amount administered is between about 100 µg and 500 mg. More preferably, the conjugated uricase is administered in an amount between 1 mg and 100 mg, such as, for example, 5 mg, 20 mg or 50 mg. Masses given for dosage amounts of the embodiments refer to the amount of protein in the conjugate.

Pharmaceutical formulations containing PEG-uricase can be prepared by conventional techniques, *e.g.*, as described in Gennaro, AR (Ed.) (1990) *Remington's Pharmaceutical Sciences*, 18th Edition Easton, PA: Mack Publishing Co. Suitable excipients for the preparation of injectable solutions include, for example, phosphate buffered saline, lactated Ringer's solution, water, polyols and glycerol. Pharmaceutical compositions for parenteral injection comprise pharmaceutically acceptable sterile aqueous or non-aqueous liquids, dispersions, suspensions, or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. These

formulations may contain additional components, such as, for example, preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, buffers, antioxidants and diluents.

PEG-uricase may also be provided as controlled-release compositions for implantation into an individual to continually control elevated uric acid levels in body fluids. For example, polylactic acid, polyglycolic acid, regenerated collagen, poly-L-lysine, sodium alginate, gellan gum, chitosan, agarose, multilamellar liposomes and many other conventional depot formulations comprise bioerodible or biodegradable materials that can be formulated with biologically active compositions. These materials, when implanted or injected, gradually break down and release the active material to the surrounding tissue. For example, one method of encapsulating PEG-uricase comprises the method disclosed in U.S. Patent 5,653,974, which is hereby incorporated by reference. The use of bioerodible, biodegradable and other depot formulations is expressly contemplated in the present invention. The use of infusion pumps and matrix entrapment systems for delivery of PEG-uricase is also within the scope of the present invention. PEG-uricase may also advantageously be enclosed in micelles or liposomes. Liposome encapsulation technology is well known in the art. See, e.g., Lasic, D, *et al.*, (Eds.) (1995) *Stealth Liposomes*. Boca Raton, FL: CRC Press.

The PEG-uricase pharmaceutical compositions of the invention will decrease the need for hemodialysis in patients at high risk of urate-induced renal failure, e.g., organ transplant recipients (see Venkateshan, VS, *et al.*, (1990) *Nephron* 56:317-321) and patients with some malignant diseases. In patients with large accumulations of crystalline urate (tophi), such pharmaceutical compositions will improve the quality of life more rapidly than currently available treatments.

The following examples, which are not to be construed as limiting the invention in any way, illustrate the various aspects disclosed above. These examples describe PEG-uricases prepared by coupling activated (*i.e.*, electrophilic) PEG derivatives of several sizes and compositions with naturally occurring porcine, fungal or bacterial uricases, or with recombinant soybean, porcine or pig-baboon chimeric uricases. Results of activity, solubility, stability, pharmacokinetic, pharmacodynamic and immunological studies are included. The data in Figures 8-11 provide evidence of the ability of PEG-modified PBC uricase of this invention to correct hyperuricemia and hyperuricosuria and to preserve renal structure and function in an animal model in which hyperuricemia and hyperuricosuria

occur and cause serious renal damage. Wu, X, *et al.*, (1994) *Proc Natl Acad Sci USA* 91:742-746. These examples provide guidance to one with ordinary skill in the art for producing substantially non-immunogenic conjugates of uricase that retain at least about 75% of the uricolytic activity of the unmodified enzyme.

5

### EXAMPLE 1

#### Purification of the tetrameric form of uricase

The tetrameric form of uricase (molecular weight *ca.* 140 kDa) was purified from a solution of porcine liver uricase by preparative size-exclusion or ion-exchange chromatography, followed by analytical size-exclusion chromatography. Porcine liver  
10 uricase was obtained from Sigma-Aldrich, St. Louis, MO, catalog No. U2350 or U3377; or Boehringer Mannheim, Indianapolis, IN.

Preparative and analytical size-exclusion chromatography were performed at pH 10-10.5, preferably 10.2, in 10 mM sodium carbonate buffer containing 0.1 M NaCl on Superdex 200 columns that had been previously calibrated with proteins of known  
15 molecular weight. Superdex was obtained from Amersham Pharmacia, Piscataway, NJ. Any buffer may be used that is capable of maintaining the desired pH and that is compatible with the chemistry to be used for subsequent PEG coupling. Such buffers are well known in the art. The ultraviolet absorbance of the eluate from the preparative column was monitored at 280 nm, and uricase-containing portions of the eluate corresponding to  
20 the molecular weight of the desired tetrameric form, but free of higher molecular weight species, were collected for use in synthesizing substantially non-immunogenic PEG-uricase as described in Example 2. Alternatively, tetrameric forms of uricase can be isolated using other size-exclusion media such as, for example, Superose 12 (Amersham Pharmacia) or any other medium that is compatible with mildly alkaline solutions and that has an  
25 appropriate size fractionation range. Such media are readily available and are well known in the art.

Ion-exchange chromatography was performed at pH 10-10.5, preferably 10.2, on Mono Q columns (Amersham Pharmacia, Piscataway, NJ) that had been equilibrated with 0.1 M sodium carbonate buffer. Any buffer that is compatible with the chemistry of PEG  
30 coupling and that is capable of maintaining the desired pH may be used at sufficiently low ionic strength to permit the adsorption of uricase to the column. Such buffers are well known in the art. The ultraviolet absorbance of the eluate was monitored at 280 nm during

elution of the uricase from the ion-exchange resin by increasing the ionic strength of the applied buffer solution, *e.g.* by a linear gradient of 0 to 0.5 M NaCl in the sodium carbonate buffer. Size-exclusion HPLC was then used to identify the fractions of the eluate containing the desired tetrameric form of uricase, without detectable aggregates, for the synthesis of substantially non-immunogenic PEG-uricase. Alternatively, the tetrameric form of uricase can be isolated using other ion-exchange media, such as Q-Sepharose (Amersham Pharmacia) or any other medium that is compatible with mildly alkaline solutions. Such media are readily available and are well known in the art.

Uricase activity was assayed using a modification of standard methods. *See, e.g.*, Fridovich (1965); Nishimura, *et al.*, (1979). Solutions of uric acid were prepared fresh daily in 50 mM sodium borate buffer, pH 9.2, to provide final concentrations in the assay of 6-150  $\mu$ M. Uricase preparations were diluted in this borate buffer containing bovine serum albumin (Sigma-Aldrich, St. Louis, MO, catalog No. A-7030), so that the final concentration of albumin in the assay was 0.1 mg/mL. After mixing various dilutions of the enzyme with the substrate in the wells of a microtiter plate in a microplate reader, the rate of disappearance of uric acid at 25°C was monitored at 292 nm every 4 seconds for 3 minutes. From samples in which between 10% and 40% of the substrate was consumed within 3 minutes, at least 20 data points were used to calculate the maximal rate of decrease in the absorbance per minute. One international unit (IU) of uricase activity is defined as the amount of enzyme that consumes one micromole of uric acid per minute; specific activities are expressed as IU/mg protein. Some of the data for relative uricase activities in Figures 1A-5B were obtained using 100  $\mu$ M uric acid in the assay. Other results for the velocity at 100  $\mu$ M uric acid ( $V_{100}$ ) were calculated from the values of the Michaelis constant ( $K_M$ ) and the maximal velocity ( $V_{max}$ ) for the respective enzyme preparations, using the formula:

$$V_{100} = 100 \times V_{max} / (K_M + 100)$$

where  $K_M$  is expressed in micromolar units.

## EXAMPLE 2

### PEG coupling to tetrameric porcine uricase

To a solution of tetrameric uricase in 0.1 M sodium carbonate buffer, pH 10.2, 10-200 moles of an activated derivative of monomethoxyPEG, *e.g.*, the 4-nitrophenyl carbonate (NPC-PEG), of various sizes (5 kDa to 30 kDa) were added for each mole of



uricase subunit (molecular weight 35 kDa). These and other suitable activated PEGs are available from Shearwater Polymers. Instructions for coupling these PEGs to proteins are given in the catalog of Shearwater Polymers, on the Internet at [www.swpolymers.com](http://www.swpolymers.com), and in JM Harris, *et al.*, (Eds.) (1997) *Poly(ethylene glycol) Chemistry and Biological Applications*. ACS Symposium Series 680, Washington, DC: American Chemical Society.

5 The coupling reaction was allowed to proceed at 0-8°C until the extent of PEG coupling no longer changed significantly with time. Unreacted PEG was then removed from the reaction product by chromatography and/or ultrafiltration.

The number of strands of PEG coupled per subunit of uricase was determined by an adaptation of the methods described by Kunitani, M, *et al.*, (1991) *J Chromatogr* 588:125-137; Saifer, *et al.*, (1997) and Sherman, *et al.*, (1997). Briefly, aliquots of the PEGylation reaction mixtures or fractions from the preparative ion-exchange or size-exclusion columns were characterized by analytical size-exclusion HPLC on a TSK 5,000 PW<sub>XL</sub> column at room temperature in 10 mM sodium carbonate buffer, pH 10.2, containing 0.1 M

10 NaCl. The HPLC column was obtained from TosoHaas, Montgomeryville, PA. Proteins and PEGs were monitored by ultraviolet absorbance and refractive index detectors. The amount of protein in the conjugate was calculated from the ultraviolet absorbance relative to that of the appropriate unmodified uricase standard. The amount of PEG in the conjugate was then calculated from the area of the refractive index peak, corrected for the contribution of the protein to refractive index, relative to the area of the refractive index

15 peak of the appropriate PEG standard.

Figure 2A shows the retention of activity by PEGylated porcine liver uricase as a function of the number of strands of PEG coupled per subunit. Data of the present inventors (▲, □) are compared with those of Chen, *et al.*, (1981). The data point within a

25 large circle denotes a conjugate reported to be non-immunoreactive by Chen, *et al.*, (1981). As shown in Figure 2A, conjugates of tetrameric porcine uricase with up to 6 strands of 30 kDa PEG per subunit or up to 7 strands of 5 kDa PEG per subunit retained at least 75% of the activity of the unmodified enzyme. The apparent increase in specific activity with an increasing number of strands of 5 kDa or 30 kDa PEG (up to about 4 strands per subunit)

30 may reflect the relative insolubility or instability of the unmodified enzyme compared to the conjugates. As shown in Figure 2B, conjugates of porcine uricase with an average of

more than 3 strands of 30 kDa PEG per subunit contain a greater mass of PEG than was found sufficient to preclude immunoreactivity by Chen, *et al.*, (1981).

### EXAMPLE 3

#### Properties of PEG conjugates of tetrameric recombinant PBC uricase

5        Recombinant pig-baboon chimeric (PBC) uricase cDNA was subcloned into the pET3d expression vector (Novagen, Madison, WI) and the resultant plasmid construct was transformed into and expressed in a strain of *Escherichia coli* BL21(DE3)pLysS (Novagen). These procedures were carried out using methods well known in the art of molecular biology. See Erlich (1989); Sambrook, *et al.*, (1989); Ausubel, F, *et al.*, (Eds.),  
10        (1997) *Short Protocols in Molecular Biology*. New York: John Wiley & Sons.

Figure 6 shows the deduced amino acid sequence of PBC uricase (amino acids 1-225 of SEQ ID NO: 1 and amino acids 226-304 of SEQ ID NO: 2), compared with the porcine (SEQ ID NO: 1) and baboon (SEQ ID NO: 2) sequences. Residues in the baboon sequence that differ from those in the porcine sequence are shown in **bold type**. The  
15        porcine and baboon sequences were first determined by Wu, *et al.*, (1989) and were confirmed by the present inventors. SEQ ID NO. 1 is identical to Accession Number p16164 of GenBank, except for the absence of the initial methionyl residue in the GenBank sequence. SEQ ID NO. 2 is identical to Accession Number p25689 of GenBank, except for the absence of the initial methionyl residue and a change from histidine to threonine at  
20        residue 153 in the GenBank sequence (residue 154 in Figure 6).

The tetrameric form of PBC uricase was isolated and coupled to PEGs of various molecular weights as described in Examples 1 and 2. Conjugates prepared with 5 kDa, 10 kDa, 19 kDa or 30 kDa PEG contained up to 10 strands of PEG per subunit. Those prepared with PEGs of at least 10 kDa retained more than 95% of the initial specific  
25        activity of the recombinant uricase (Figures 3A-3B).

The following properties of a conjugate of tetrameric PBC uricase with approximately 6 strands of 10 kDa PEG per subunit are illustrated in the indicated figures: the lack of immunogenicity (Figure 7) and the efficacy in uricase-deficient mice in  
30        1) correcting hyperuricemia and hyperuricosuria (Figure 8); 2) decreasing the severity of a urine-concentrating defect (Figure 9), and 3) decreasing the severity of nephrogenic diabetes insipidus (Figure 10). In addition, this PEG-uricase decreased the severity of uric acid-related renal damage, as visualized by magnetic resonance microscopy (Figure 11).

Figure 7 shows the activity of PBC uricase in mouse serum 24 h after each of four or five intraperitoneal injections of PEG-uricase, relative to the value 24 h after the first injection. PEG conjugates were prepared from three different preparations of PBC uricase using two different techniques for PEG activation. One preparation (●) was tested in uricase-deficient (*uox* <sup>-/-</sup>) mice; the other two (Δ, ■) were tested in normal BALB/c mice. The most immunoreactive preparation (Δ) was prepared from purified PBC uricase containing an unknown quantity of uricase aggregates coupled to an average of 7 strands of 5 kDa PEG per subunit, using the succinimidyl carbonate derivative of PEG (SC-PEG). Zalipsky, U.S. Patent 5,612,460, hereby incorporated by reference. The moderately immunoreactive preparation (■) was prepared by coupling a PBC uricase preparation containing 11% aggregates to an average of 2 strands of 19 kDa PEG per subunit, using a 4-nitrophenyl carbonate derivative of PEG (NPC-PEG). Sherman, *et al.*, (1997). The least immunoreactive conjugate (●) was prepared by coupling an average of 6 strands of 10 kDa NPC-PEG per subunit to a preparation of PBC uricase containing <5% aggregated uricase.

Figure 8 shows the inverse relationship between the concentrations of uric acid in the serum and urine and the activity of injected PEG-uricase in the serum of a uricase-deficient (*uox* <sup>-/-</sup>) mouse. Injections at zero time and after 72 h contained 0.43 IU of PBC uricase conjugated to an average of 6 strands of 10 kDa PEG per enzyme subunit.

Figure 9 shows that treatment of uricase-deficient mice with PEG-modified PBC uricase decreased the severity of a urine-concentrating defect. The mean and standard deviation of data for urine osmolality are shown for two mice containing one copy of the normal murine uricase gene (*uox* <sup>+/-</sup>), six untreated homozygous uricase-deficient mice (*uox* <sup>-/-</sup>) and six homozygous uricase-deficient mice that were injected ten times between the third and 72nd day of life with either 95 or 190 mIU of PEG-uricase. Mice of each genetic background either had received water *ad libitum* (*solid bars*) or had been deprived of water for 12 h (*hatched bars*) prior to collection of their urine.

Figure 10 shows that treatment of uricase-deficient mice with PEG-modified PBC uricase decreased the severity of nephrogenic diabetes insipidus, characterized by abnormally high consumption of water and abnormally high urine output. The genetic backgrounds of the mice and treatment protocol were the same as in Figure 9. The mean

and standard deviation of the daily water consumption (*solid bars*) and urine output (*hatched bars*) are shown for three groups of six mice.

Figure 11 shows that treatment of uricase-deficient mice with PEG-modified PBC uricase decreased the severity of uric acid-induced nephropathy, as visualized by magnetic resonance microscopy. The genetic backgrounds of the three groups of mice and the treatment protocol were the same as in Figures 9 and 10. Magnetic resonance microscopy was performed at the Center for *in vivo* Microscopy, Duke University Medical Center, Durham, North Carolina.

In addition to the results summarized in Figures 8-11, it was demonstrated that the uric acid levels in the urine of all uricase-deficient mice decreased dramatically after treatment with PEG-modified PBC uricase. Finally, Figure 12 shows that, unlike the PEG-modified tetrameric form of PBC uricase, the octameric form (molecular weight = 280 kDa), even when extensively PEGylated, is immunogenic in mice. This property is reflected in the accelerated clearance of the PEG-modified octamer within 5 days after a single intraperitoneal injection. The same mice were re-injected with the same dose of the same PEG-uricase preparations on days 8 and 15. Twenty-four hours after the second and third injections, uricolytic activity was undetectable in the sera of mice injected with the PEGylated octamer, but was readily detected in the sera of those injected with the PEGylated tetramer. These findings, in combination with the accelerated clearance of the PEGylated octamer observed after the first injection (Figure 12), support the utility of removing all forms of uricase larger than the tetramer prior to PEGylation of the enzyme.

#### EXAMPLE 4

##### PEG conjugation of uricase from *Candida utilis*

Uricase from *Candida utilis* was obtained from either Sigma-Aldrich (St. Louis, MO; catalog No. U1878) or Worthington Biochemical Corporation (Freehold, NJ; catalog No. URYW). Proceeding as described in Examples 1 and 2, the tetrameric form was isolated and PEG conjugates were synthesized with 5 kDa, 10 kDa or 30 kDa PEG (Figures 1A-1B). Figure 1A shows the retention of activity by PEGylated uricase from *Candida utilis* as a function of the number of strands of PEG coupled per subunit. Data of the present inventors ( $\blacktriangle$ ,  $\bullet$ ,  $\square$ ) are compared with those of Nishimura, *et al.*, (1979); Nishimura, *et al.*, (1981); Chen, *et al.*, (1981); Davis, *et al.*, (1981); Tsuji, *et al.*, (1985); Yasuda, *et al.*, (1990), and Fujita, *et al.*, (1991). Data points within large circles denote

conjugates reported to be non-antigenic by Nishimura, *et al.*, (1979 or 1981) or non-immunoreactive by Chen, *et al.*, (1981).

Figure 1B shows the retention of activity by PEGylated uricase from *Candida utilis* as a function of the total mass of PEG coupled per subunit. Data of the present inventors (▲, ●, □) are compared with those of the same reports as in Figure 1A. Data points within large circles have the same meaning as in Figure 1A.

As shown in Figures 1A and 1B, conjugates with an average of up to 6 strands of 5 kDa or 30 kDa PEG or 9 strands of 10 kDa PEG per subunit retained at least 75% of the activity of the unmodified enzyme. The apparent increase in specific activity as an increasing number of strands of 30 kDa PEG is attached (up to 5 or 6 strands per subunit) may reflect the relative insolubility or instability of the unmodified enzyme compared to the conjugates.

#### EXAMPLE 5

##### PEG conjugation of uricase from *Aspergillus flavus*

Uricase from *Aspergillus flavus* was obtained from Sanofi Winthrop (Gentilly Cédex, France). Proceeding as described in Example 2, conjugates with PEGs of various molecular weights were synthesized (Figures 4A-4B). Conjugates prepared by coupling the enzyme from *A. flavus* with an average of up to 12 strands of 5 kDa PEG or up to 7 strands of 30 kDa PEG per subunit retained at least 75% of the initial specific activity of this fungal uricase.

#### EXAMPLE 6

##### PEG conjugation of soybean uricase

Recombinant uricase from soybean root nodule (also called nodulin 35) was prepared and purified as described by Kahn and Tipton (Kahn, K, *et al.*, (1997) *Biochemistry* 36:4731-4738), and was provided by Dr. Tipton (University of Missouri, Columbia, MO). Proceeding as described in Examples 1 and 2, the tetrameric form was isolated and conjugates were prepared with PEGs of various molecular weights (Figures 5A-5B). In contrast to uricase from *Candida utilis* (Figure 1A), porcine uricase (Figure 2A), pig-baboon chimeric uricase (Figure 3A) and uricase from *Aspergillus flavus* (Figure 4A), the soybean enzyme tolerated coupling of only approximately 2 strands of 5 kDa or 30 kDa PEG per subunit with retention of at least 75% of the initial uricolytic activity.

**EXAMPLE 7**PEG conjugation of uricase from *Arthrobacter globiformis*

Uricase from *Arthrobacter globiformis* was obtained from Sigma-Aldrich (catalog No. U7128). See Japanese Patent 9-154581. Proceeding as described in Examples 1 and 2, the tetrameric form was isolated and conjugates with 5 kDa and 30 kDa PEG were prepared. While conjugates with an average of more than 3 strands of 5 kDa PEG per subunit retained less than 60% of the initial specific activity, conjugates with an average of approximately 2 strands of 30 kDa PEG per subunit retained at least 85% of the initial specific activity.

**EXAMPLE 8**PEG conjugation of amino-truncated porcine and PBC uricases

Recombinant porcine and PBC uricases from which the first six amino acids at the amino terminal are deleted are expressed in and purified from *E. coli* by standard techniques, as described in Example 3. Proceeding as described in Examples 1 and 2, PEG conjugates of the amino-truncated uricases are synthesized to produce substantially non-immunogenic conjugates that retain at least 75% of the initial specific activity.

**EXAMPLE 9**PEG conjugation of porcine and PBC uricases truncated at the carboxyl terminal or both the amino and carboxyl terminals

Recombinant porcine and PBC uricases from which the last three amino acids at the carboxyl terminal are deleted are expressed in and purified from *E. coli* by standard techniques, as described in Example 3. This carboxyl-terminal deletion may enhance the solubility of the unmodified enzymes, since it removes the peroxisomal-targeting signal. See Miura, *et al.*, (1994). Proceeding as described in Examples 1 and 2, PEG conjugates of the carboxyl-truncated uricases are synthesized to produce substantially non-immunogenic conjugates that retain at least 75% of the initial specific activity. The sequence of recombinant PBC uricase truncated by six residues at the amino terminal and by three residues at the carboxyl terminal (PBC-NT-CT) is shown in Figure 6. This uricase is expressed, purified and PEGylated as described in Examples 1, 2 and 3 to produce substantially non-immunogenic conjugates that retain at least 75% of the initial specific activity.

**EXAMPLE 10****PEG conjugation of porcine uricase mutants containing  
an increased number of PEG attachment sites**

Recombinant porcine uricases are prepared as described in Example 3, in which the  
5 potential number of sites of PEG attachment is increased by replacing one or more arginine  
residues with lysine. See Hershfield, MS, *et al.*, (1991) *Proc Natl Acad Sci USA* 88:7185-  
7189. The amino acid sequence of one example of such a mutant (PKS uricase), in which  
the arginine at residue 291 is replaced by lysine and the threonine at residue 301 is replaced  
by serine, is shown in Figure 6. Proceeding as described in Examples 1 and 2, PEG is  
10 conjugated to this uricase to produce substantially non-immunogenic conjugates that retain  
at least 75% of the initial specific activity of the recombinant uricase.

**EXAMPLE 11****PEG conjugation of a recombinant baboon uricase mutant**

Using standard methods of molecular biology, as in Example 3, recombinant  
15 baboon uricase is constructed having an amino acid substitution (histidine for tyrosine) at  
position 97 (*see* baboon sequence in Figure 6). Proceeding as described in Examples 1 and  
2, PEG conjugates of the tetrameric form of the recombinant baboon uricase mutant are  
synthesized to produce conjugates of substantially reduced immunogenicity that retain at  
least 75% of the initial specific activity of the recombinant uricase.

**EXAMPLE 12****Immunogenicity of PEG conjugates from *Candida utilis*, *Aspergillus flavus*,  
and *Arthrobacter globiformis***

Uricase from *Candida utilis*, *Aspergillus flavus*, and *Arthrobacter globiformis* are  
obtained as described in Examples 4, 5, and 7, respectively. Proceeding as described in  
25 Examples 1 and 2, PEG conjugates are synthesized with 5 kDa, 10 kDa, 20 kDa or 30 kDa  
PEG. The immunogenicity of these conjugates is substantially reduced or eliminated.

WHAT IS CLAIMED IS:

1. A conjugate of uricase that retains at least about 75% of the uricolytic activity of unconjugated uricase and is substantially non-immunogenic, comprising a purified uricase comprising subunits in which each subunit of the uricase is covalently linked to an average of  
5 2 to 10 strands of PEG, wherein each molecule of PEG has a molecular weight between about 5 kDa and 100 kDa.
2. The conjugate of Claim 1, wherein the uricase is mammalian uricase.
3. The conjugate of Claim 2, wherein the uricase is porcine liver, bovine liver or  
ovine liver uricase.
- 10 4. The conjugate of Claim 1, wherein the uricase is recombinant.
5. The conjugate of Claim 4, wherein the uricase has substantially the sequence of porcine, bovine, ovine or baboon liver uricase.
6. The conjugate of Claim 4, wherein the uricase is chimeric.
7. The conjugate of Claim 6, wherein the chimeric uricase contains portions of  
15 porcine liver and baboon liver uricase.
8. The conjugate of Claim 7, wherein the chimeric uricase is PBC uricase.
9. The conjugate of Claim 7, wherein the chimeric uricase is PKS uricase.
10. The conjugate of Claim 4, wherein the uricase has substantially the sequence of baboon liver uricase in which tyrosine 97 has been replaced by histidine.
- 20 11. The conjugate of Claim 4, wherein the uricase comprises an amino terminal and a carboxyl terminal, and wherein the uricase is truncated at one terminal or both terminals.
12. The conjugate of Claim 1, wherein the uricase is a fungal or microbial uricase.
13. The conjugate of Claim 12, wherein the fungal or microbial uricase is isolated  
from *Aspergillus flavus*, *Arthrobacter globiformis* or *Candida utilis*, or is a recombinant  
25 enzyme having substantially the sequence of one of those uricases.
14. The conjugate of Claim 1, wherein the uricase is an invertebrate uricase.
15. The conjugate of Claim 14, wherein the invertebrate uricase is isolated from *Drosophila melanogaster* or *Drosophila pseudoobscura*, or is a recombinant enzyme having  
substantially the sequence of one of those uricases.
- 30 16. The conjugate of Claim 1, wherein the uricase is a plant uricase.




17. The conjugate of Claim 16, wherein the plant uricase is isolated from root nodules of *Glycine max* or is a recombinant enzyme having substantially the sequence of that uricase.
18. The conjugate of Claim 1, wherein the PEG has an average molecular weight between about 10 kDa and 60 kDa.
- 5 19. The conjugate of Claim 18, wherein the PEG has an average molecular weight between about 20 kDa and 40 kDa.
20. The conjugate of Claim 1, wherein the average number of covalently coupled strands of PEG is 3 to 8 strands per uricase subunit.
21. The conjugate of Claim 20, wherein the average number of covalently coupled  
10 strands of PEG is 4 to 6 strands per uricase subunit.
22. The conjugate of Claim 1, wherein the uricase is tetrameric.
23. The conjugate of Claim 1, wherein the strands of PEG are covalently coupled to uricase via linkages selected from the group consisting of urethane linkages, secondary amine linkages, and amide linkages.
- 15 24. The conjugate of Claim 1, wherein the PEG is linear.
25. The conjugate of Claim 1, wherein the PEG is branched.
26. A pharmaceutical composition for lowering uric acid levels in a body fluid or tissue, comprising the conjugate of Claim 1 and a pharmaceutically acceptable carrier.
27. The pharmaceutical composition of Claim 26, wherein said composition is  
20 stabilized by lyophilization and dissolves promptly upon reconstitution to provide solutions suitable for parenteral administration.
28. A method for lowering elevated uric acid levels in a body fluid or tissue of a mammal, comprising the step of administering to said mammal an effective uric acid-lowering amount of PEG-uricase, said PEG-uricase comprising a purified uricase comprising at least  
25 two subunits in which each subunit is covalently linked to an average of 2 to 10 strands of PEG, wherein each molecule of PEG has a molecular weight between about 5 kDa and 100 kDa, in a pharmaceutically acceptable carrier.
29. The method of Claim 28, wherein said mammal is a human.

30. The method of Claim 28, wherein the administering step is selected from the group consisting of injections by intravenous, intradermal, subcutaneous, intramuscular and intraperitoneal routes or inhalation of an aerosolized formulation.
31. The method of Claim 28, wherein said elevated uric acid levels are associated with a condition selected from the group consisting of gout, tophi, renal insufficiency, organ transplantation and malignant disease.
32. The method of Claim 28, wherein the PEG is linear.
33. The method of Claim 28, wherein the PEG is branched.
34. A method for isolating a tetrameric form of uricase from a solution of uricase, said solution comprising tetrameric uricase and uricase aggregates, comprising the steps of:  
applying said solution to at least one separation column at a pH between about 9 and 10.5; and  
recovering from said column one or more fractions that contain isolated tetrameric uricase, wherein said one or more fractions are substantially free of uricase aggregates.
35. The method of Claim 34, wherein said solution of said uricase is applied to said column at a pH of 10.2.
36. The method of Claim 34, wherein said separation is based on a property selected from the group consisting of ion exchange and size exclusion.
37. The method of Claim 34, further comprising the step of analyzing said fractions to determine at least one property selected from the group consisting of presence of said tetrameric uricase and absence of uricase aggregates.
38. The method of Claim 37, wherein said analyzing step comprises at least one analysis selected from the group consisting of chromatography, centrifugation, light scattering and electrophoresis.
39. The method of Claim 38, wherein said chromatography is high performance liquid chromatography.
40. The method of Claim 34, wherein said isolated tetrameric uricase contains less than about 10% uricase aggregates.
41. An isolated tetrameric uricase produced by the method of Claim 34.


1/17

**FIG. 1A** Retention of Activity by PEGylated Candida Uricase




2/17

**FIG. 1B** Retention of Activity by PEGylated Candida Uricase




3/17




4/17

**FIG. 2B** Retention of Activity by PEGylated Porcine Uricase




5/17




SUBSTITUTE SHEET (RULE26)

6/17







7/17




8/17



9/17



10/17



11/17


**FIG. 6**

Deduced Amino Acid Sequences of Pig-Baboon Chimeric Uricase (PBC Uricase),  
PBC Uricase Truncated at the Amino and Carboxyl Terminals (PBC-NT-CT)  
and Porcine Uricase Containing the Mutations R291K and T301S (PKS Uricase),  
Compared with the Porcine and Baboon Sequences


Porcine	MAHYRNDYKK	NDEVEFVRTG	YGKDMIKVLH	IQRDGKYHSI	40
PBC	porcine sequence 1-225 →				40
PBC-NT-CT	porcine sequence 1-219 →				34
PKS	porcine sequence 1-288 →				40
Baboon	MADYHNNYKK	NDELEFVRTG	YGKDMVKVLH	IQRDGKYHSI	40
Porcine	KEVATSVQLT	LSSKKDYLHG	DNSDVIPTDT	IKNTVNVLAK	80
PBC	porcine sequence →				80
PBC-NT-CT	porcine sequence →				74
PKS	porcine sequence →				80
Baboon	KEVATSVQLT	LSSKKDYLHG	DNSDIIPTDT	IKNTVHVLAK	80
Porcine	FKGIKSIETF	AVTICEHFLS	SFKHVIRAQV	YVEEVPWKRF	120
PBC	porcine sequence →				120
PBC-NT-CT	porcine sequence →				114
PKS	porcine sequence →				120
Baboon	FKGIKSIEAF	GVNICEYFLS	SFNHVIRAQV	YVEEIPWKRL	120
Porcine	EKNGVKHVHA	FIYPTGTGTHF	CEVEQIRNGP	PVIHSGIKDL	160
PBC	porcine sequence →				160
PBC-NT-CT	porcine sequence →				154
PKS	porcine sequence →				160
Baboon	EKNGVKHVHA	FIHTPTGTGTHF	CEVEQLRSGP	PVIHSGIKDL	160
Porcine	KVLKTTQSGF	EGFIKDQFTT	LPEVKDRCFA	TQVYCKWRYH	200
PBC	porcine sequence →				200
PBC-NT-CT	porcine sequence →				194
PKS	porcine sequence →				200
Baboon	KVLKTTQSGF	EGFIKDQFTT	LPEVKDRCFA	TQVYCKWRYH	200
Porcine	QGRDVFDEAT	WDTVRSIVLQ	KFAGPYDKGE	YSPSVQKTLY	240
PBC	porcine sequence →   ← baboon sequence				240
PBC-NT-CT	porcine sequence →   ← baboon sequence				234
PKS	porcine sequence →				240
Baboon	QCRDVFDEAT	WGTIRDLVLE	KFAGPYDKGE	YSPSVQKTLY	240
Porcine	DIQVLTGLQV	PEIEDMEISL	PNIHYLNIDM	SKMGLINKEE	280
PBC	baboon sequence →				280
PBC-NT-CT	baboon sequence →				274
PKS	porcine sequence →				280
Baboon	DIQVLSLSRV	PEIEDMEISL	PNIHYFNIDM	SKMGLINKEE	280
Porcine	VLLPLDNPYG	RITGTVKRKL	TSRL	304	
PBC	baboon sequence →				304
PBC-NT-CT	baboon sequence →				295
PKS	porcine   ← baboon →				304
Baboon	VLLPLDNPYG	KITGTVKRKL	SSRL	304	

12/17

FIG. 7 Serum Uricase Activity 24 Hours after Each  
PEG-Uricase Injection, Relative to the First Injection




**FIG. 8** Inverse Relationship between serum PEG-Uricase Activity and Uric Acid Levels in the Serum and Urine of a Uricase-Deficient Mouse



14/17


**FIG. 9** Decreased Severity of Urine-Concentrating Defect in Uricase-Deficient Mice Treated with PEG-Uricase






15/17

**FIG. 10** Decreased Severity of Nephrogenic Diabetes Insipidus in Uricase-Deficient Mice Treated with PEG-Uricase




*FIG. 11*

Decreased Severity of Uric Acid-Induced Nephropathy after Treatment with PEG-Uricase, as Visualized by Magnetic Resonance Microscopy



17/17

**FIG. 12** Clearance from the Circulation of BALB/c Mice of PBC Uricase Tetramer and Octamer coupled to 5-6 Strands of 10-kDa PEG/Subunit



## SEQUENCE LISTING

<110> Williams, L. David  
 Hershfield, Michael S.  
 Kelly, Susan J.  
 Saifer, Mark G.P.  
 Sherman, Merry R.

<120> PEG-URATE OXIDASE CONJUGATES AND USE  
 THEREOF

<130> MVIEW.001VPC

<140>

<141>

<150> 09/130,392

<151> 1998 08-06

<160> 2

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 304

<212> PRT

<213> Sus scrofa

<400> 1

```

Met Ala His Tyr Arg Asn Asp Tyr Lys Lys Asn Asp Glu Val Glu Phe
 1           5           10           15
Val Arg Thr Gly Tyr Gly Lys Asp Met Ile Lys Val Leu His Ile Gln
 20           25           30
Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln
 35           40           45
Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp
 50           55           60
Val Ile Pro Thr Asp Thr Ile Lys Asn Thr Val Asn Val Leu Ala Lys
 65           70           75           80
Phe Lys Gly Ile Lys Ser Ile Glu Thr Phe Ala Val Thr Ile Cys Glu
 85           90           95
His Phe Leu Ser Ser Phe Lys His Val Ile Arg Ala Gln Val Tyr Val
 100          105          110
Glu Glu Val Pro Trp Lys Arg Phe Glu Lys Asn Gly Val Lys His Val
 115          120          125
His Ala Phe Ile Tyr Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu
 130          135          140
Gln Ile Arg Asn Gly Pro Val Ile His Ser Gly Ile Lys Asp Leu
 145          150          155          160
Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp
 165          170          175
Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln
 180          185          190
Val Tyr Cys Lys Trp Arg Tyr His Gln Gly Arg Asp Val Asp Phe Glu
 195          200          205
Ala Thr Trp Asp Thr Val Arg Ser Ile Val Leu Gln Lys Phe Ala Gly
 210          215          220
Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr
 225          230          235          240
Asp Ile Gln Val Leu Thr Leu Gly Gln Val Pro Glu Ile Glu Asp Met
 245          250          255

```

Glu Ile Ser Leu Pro Asn Ile His Tyr Leu Asn Ile Asp Met Ser Lys  
 260 265 270  
 Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro  
 275 280 285  
 Tyr Gly Arg Ile Thr Gly Thr Val Lys Arg Lys Leu Thr Ser Arg Leu  
 290 295 300

<210> 2  
 <211> 304  
 <212> PRT  
 <213> Papio hamadryas

<400> 2  
 Met Ala Asp Tyr His Asn Asn Tyr Lys Lys Asn Asp Glu Leu Glu Phe  
 1 5 10 15  
 Val Arg Thr Gly Tyr Gly Lys Asp Met Val Lys Val Leu His Ile Gln  
 20 25 30  
 Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln  
 35 40 45  
 Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp  
 50 55 60  
 Ile Ile Pro Thr Asp Thr Ile Lys Asn Thr Val His Val Leu Ala Lys  
 65 70 75 80  
 Phe Lys Gly Ile Lys Ser Ile Glu Ala Phe Gly Val Asn Ile Cys Glu  
 85 90 95  
 Tyr Phe Leu Ser Ser Phe Asn His Val Ile Arg Ala Gln Val Tyr Val  
 100 105 110  
 Glu Glu Ile Pro Trp Lys Arg Leu Glu Lys Asn Gly Val Lys His Val  
 115 120 125  
 His Ala Phe Ile His Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu  
 130 135 140  
 Gln Leu Arg Ser Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu  
 145 150 155 160  
 Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp  
 165 170 175  
 Gln Phe Thr Thr Lys Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln  
 180 185 190  
 Val Tyr Cys Lys Trp Arg Tyr His Gln Cys Arg Asp Val Asp Phe Glu  
 195 200 205  
 Ala Thr Trp Gly Thr Ile Arg Asp Leu Val Leu Glu Lys Phe Ala Gly  
 210 215 220  
 Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr  
 225 230 235 240  
 Asp Ile Gln Val Leu Ser Leu Ser Arg Val Pro Glu Ile Glu Asp Met  
 245 250 255  
 Glu Ile Ser Leu Pro Asn Ile His Tyr Phe Asn Ile Asp Met Ser Lys  
 260 265 270  
 Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro  
 275 280 285  
 Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Arg Leu  
 290 295 300

**THIS PAGE BLANK (USPTO)**

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/17514

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K47/48 A61K38/44 C12N9/06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEN R H -L ET AL: "PROPERTIES OF TWO URATE OXIDASES MODIFIED BY THE COVALENT ATTACHMENT OF POLY(ETHYLENE GLYCOL)" BBA ENZYMOLOGY,NL,ELSEVIER, AMSTERDAM, vol. 660, no. 2, page 293-298 XP000577602 ISSN: 0005-2744 cited in the application abstract	1-3, 23-33
Y	---	1-33
X	DAVIS S ET AL: "HYPOURICAEMIC EFFECT OF POLYETHYLENEGLYCOL MODIFIED URATE OXIDASE" LANCET THE,GB,LANCET LIMITED. LONDON, page 281-283 XP000577404 ISSN: 0140-6736 cited in the application abstract	1, 12, 13, 20, 21, 23-33
Y	---	1-33
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

Date of the actual completion of the international search

6 March 2000

Date of mailing of the international search report

17: 03: 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Herrera, S

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/17514

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	YASUDA Y. ET AL: "Biochemical and biopharmaceutical properties of macromolecular conjugates of uricase with dextran and polyethylene glycol." CHEMICAL AND PHARMACEUTICAL BULLETIN, (1990) 38/7 (2053-2056)., XP002125209 cited in the application abstract	1,12,13, 20,21, 23-33
Y	---	1-33
Y	OSMAN A M ET AL: "Liver uricase in Camelus dromedarius: purification and properties." COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY. B: COMPARATIVE BIOCHEMISTRY, (1989) 94 (3) 469-74., XP002125210 abstract page 471, left-hand column, line 8-13	1-33
X	---	
X	CHUA C C ET AL: "Use of polyethylene glycol-modified uricase ( PEG - uricase ) to treat hyperuricemia in a patient with non-Hodgkin lymphoma." ANNALS OF INTERNAL MEDICINE, (1988 JUL 15) 109 (2) 114-7., XP002125211 cited in the application abstract	1,12,13, 20,21, 23-33
Y	---	1-33
X	SAVOCA K V ET AL: "Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modified uricase." INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, (1984) 75 (1) 58-67., XP002125212 cited in the application abstract	1,12,13, 20,21, 23-33
Y	---	1-33
Y	SUZUKI H ET AL: "SOYBEAN NODULE-SPECIFIC URICASE NODULIN 35 IS EXPRESSED AND ASSEMBLED INTO A FUNCTIONAL TETRAMERIC HOLOENZYME IN ESCHERICHIA-COLI." PLANT PHYSIOL (BETHESDA), (1991) 95 (2), 384-389., XP002125213 abstract	1-33
A	---	
A	BURNHAM N L: "Polymers for delivering peptides and proteins." AMERICAN JOURNAL OF HOSPITAL PHARMACY, (1994 JAN 15) 51 (2) 210-8;QUIZ 228-9. REF: 47, XP000783643 page 215, right-hand column, paragraph 2	
	---	
	-/--	



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/17514

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MONTALBINI, P. ET AL: "Uricase from leaves: Its purification and characterization from three different higher plants." PLANTA (HEIDELBERG), (1997) VOL. 202, NO. 3, PP. 277-283. , XP000881523 page 277-278	34, 36-38,41
A	-----	34-41

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 99/17514

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 99/17514

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-33

PEG-uricase conjugates wherein each subunit of the uricase is linked to an average of 2-10 strands of PEG and wherein the PEG has a molecular weight of 5-100 kDa

2. Claims: 34-41

A method of isolating a tetrameric form of uricase using pH of 9-10.5

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**